Q: Why do early phase oncology trials rarely go exactly as planned?
The plan is based on controlled assumptions, but early-phase oncology is anything but controlled. FIH exposures involve evolving mechanisms and patients who are often heavily pretreated with biology that doesn’t behave predictably. On paper, the protocol appears straightforward, with dose levels, DLT windows, and escalation rules. But once patients start enrolling, reality starts to challenge these assumptions. You see unexpected toxicities, delayed effects, or sometimes no signal where you thought there would be one.
There’s also a gap between our expectations of how a drug will behave and its actual behavior in humans. Preclinical models can provide guidance, but they don’t fully capture the complexity of immune systems, tumor microenvironments, or prior lines of therapy. Consequently, timelines shift, cohorts expand, and eligibility criteria either tighten or loosen. The protocol begins to evolve, not due to poor design, but because it’s being stress-tested in real time.
And then there’s the operational side, which people often underestimate. Sites interpret criteria differently, and data arrives in delayed or incomplete forms. Safety signals aren’t always immediately obvious; they show up as patterns rather than isolated events. As a medical monitor, you’re constantly recalibrating your approach. You don’t react blindly, but you also don’t rigidly stick to the original plan when the data clearly telling a different story. That’s the part that doesn’t get talked about enough. Early phase trials aren’t meant to run perfectly; they’re meant to learn from. The protocol is a starting point, not a fixed script.
Key takeaway: If an early oncology trial is going exactly as planned, you should probably be asking what you’re missing. The true value isn’t in execution alone, but in how quickly and thoughtfully you adapt when reality diverges from expectation.